Jackson Hole Capital Partners LLC Acquires 1,241 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Jackson Hole Capital Partners LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,592 shares of the biopharmaceutical company’s stock after buying an additional 1,241 shares during the period. Jackson Hole Capital Partners LLC’s holdings in Gilead Sciences were worth $1,587,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Strategic Blueprint LLC grew its holdings in shares of Gilead Sciences by 8.1% during the 3rd quarter. Strategic Blueprint LLC now owns 4,388 shares of the biopharmaceutical company’s stock worth $329,000 after purchasing an additional 328 shares in the last quarter. Proficio Capital Partners LLC acquired a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $207,000. Koshinski Asset Management Inc. grew its holdings in shares of Gilead Sciences by 5.1% during the 3rd quarter. Koshinski Asset Management Inc. now owns 2,975 shares of the biopharmaceutical company’s stock worth $223,000 after purchasing an additional 145 shares in the last quarter. DeDora Capital Inc. grew its holdings in shares of Gilead Sciences by 13.1% during the 3rd quarter. DeDora Capital Inc. now owns 10,114 shares of the biopharmaceutical company’s stock worth $758,000 after purchasing an additional 1,170 shares in the last quarter. Finally, Measured Wealth Private Client Group LLC grew its holdings in shares of Gilead Sciences by 11.9% during the 3rd quarter. Measured Wealth Private Client Group LLC now owns 13,931 shares of the biopharmaceutical company’s stock worth $1,044,000 after purchasing an additional 1,478 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on GILD shares. Royal Bank of Canada decreased their price target on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating on the stock in a research note on Wednesday, February 14th. StockNews.com lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, April 19th. UBS Group decreased their price target on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Mizuho decreased their price target on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, February 22nd. Finally, Barclays decreased their price target on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a research note on Monday, February 12th. Ten analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Gilead Sciences presently has an average rating of “Hold” and a consensus price target of $84.57.

Gilead Sciences Trading Down 2.7 %

Shares of GILD stock traded down $1.81 on Thursday, reaching $65.27. 15,163,484 shares of the stock were exchanged, compared to its average volume of 7,415,576. The stock has a market cap of $81.27 billion, a PE ratio of 14.50, a P/E/G ratio of 0.96 and a beta of 0.19. Gilead Sciences, Inc. has a one year low of $65.09 and a one year high of $87.86. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. The stock has a 50 day moving average price of $71.40 and a 200 day moving average price of $76.32.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The company had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.37 earnings per share. Equities research analysts forecast that Gilead Sciences, Inc. will post 5.24 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were given a dividend of $0.77 per share. The ex-dividend date was Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.72%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. Gilead Sciences’s payout ratio is presently 68.44%.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.